Page 19 - Journal of Structural Heart Disease Volume 1, Issue 3

125
Original Scientific Article
Nevertheless, continuous effort to develop, improve and clinically evaluate these devices and techniques will eventually enable safe alternative to aortic valve surgery for an increasing number of patients.
Conflict of Interest
Dr. Makkar is a consultant and has received grant support from Edwards Lifesciences Corporation, Medtronic Inc., and St. Jude Medical; and holds equity
in Entourage Medical. Dr. Jilaihawi is a consultant for Edwards Lifesciences Corporation, St. Jude Medical, and Venus MedTech.
Comment on this Article or Ask a Question
References
1. Makkar RR, Fontana GP, Jilaihawi H, Kapa- dia S, Pichard AD, Douglas PS, et al. Tran- scatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696-1704. DOI: 10.1056/ NEJMoa1202277
2. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686-1695. DOI: 10.1056/NEJ- Moa1200384
3. Cribier A, Eltchaninoff H, Bash A, Boren- stein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation. 2002;106:3006-3008. DOI: 10.1161/01. CIR.0000047200.36165.B8
4. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Tran- scatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-1798. DOI: 10.1056/NEJ- Moa1400590
5. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, Treede H, et al. Thirty-day re- sults of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPI- EN valve. Circulation. 2010;122:62-69. DOI: 10.1161/CIRCULATIONAHA.109.907402
6. Gilard M, Eltchaninoff H, Iung B, Donzeau- Gouge P, Chevreul K, Fajadet J, et al. Reg- istry of transcatheter aortic-valve implan- tation in high-risk patients. N Engl J Med. 2012;366:1705-1715. DOI: 10.1056/NEJ- Moa1114705
7. Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G, et al. In- cidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe
aortic stenosis. Circulation. 2011;123:299- 308. DOI: 10.1161/CIRCULATIONA- HA.110.946533
8. Lerakis S, Hayek SS, Douglas PS. Para- valvular aortic leak after transcatheter aortic valve replacement: current knowl- edge. Circulation. 2013;127:397-407. DOI: 10.1161/CIRCULATIONAHA.112.142000
9. Généreux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, et al. Paravalvu- lar leak after transcatheter aortic valve replacement: the new Achilles’ heel? A comprehensive review of the literature. J Am Coll Cardiol. 2013;61:1125-1136. DOI: 10.1016/j.jacc.2012.08.1039
10. Moat NE, Ludman P, de Belder MA, Bridge- water B, Cunningham AD, Young CP, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk pa- tients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Car- diol. 2011;58:2130-2138. DOI: 10.1016/j. jacc.2011.08.050
11. Fassa A-A, Himbert D, Vahanian A. Mech- anisms and management of TAVR-related complications. Nat Rev Cardiol. 2013;10: 685-695. DOI: 10.1038/nrcardio.2013.156
12. Binder RK, Rodés-Cabau J, Wood DA, Webb JG. Edwards SAPIEN 3 valve. EuroIn- tervention. 2012;8(Suppl. Q):Q83-87. DOI: 10.4244/EIJV8SQA15
13. Binder RK, Rodés-Cabau J, Wood DA, Mok M, Leipsic J, De Larochellière R, et al. Transcatheter aortic valve replace- ment with the SAPIEN 3: a new balloon- expandable transcatheter heart valve. JACC Cardiovasc Interv. 2013;6:293-300. DOI: 10.1016/j.jcin.2012.09.019
14. Webb J, Gerosa G, Lefèvre T, Leipsic J, Spen- ce M, Thomas M, et al. Multicenter evalua- tion of a next-generation balloon-expand- able transcatheter aortic valve. J Am Coll
Cardiol. 2014;64:2235-2243. DOI: 10.1016/j.
jacc.2014.09.026
15. Kodali S. Clinical and echocardiographic outcomes at 30 days with the SAPIEN 3 TAVR system in inoperable, high-risk and intermediate-risk AS patients. Presented at ACC 2015.
16. Sinning J-M, Werner N, Nickenig G, Grube E. Medtronic CoreValve Evolut valve. Eu- roIntervention. 2012;8(Suppl. Q):Q94-96. DOI: 10.4244/EIJV8SQA17
17. Fairley SL, Jeganathan R, Manoharan G, Spence MS. Early experience of implanta- tion of the new CoreValve(®) Evolut(TM) in degenerated bioprosthetic aortic valves. Catheter Cardiovasc Interv. 2014;83:485- 492. DOI: 10.1002/ccd.25125
18.Zavalloni D, De Benedictis M, Pagnotta P, Scrocca I, Presbitero P. New CoreValve Evolut 23 mm technology for treatment of degenerated bioprosthesis. Heart Lung Circ. 2014;23:183-185. DOI: 10.1016/j. hlc.2013.08.002
19.Piazza N, Martucci G, Lachapelle K, de Varennes B, Bilodeau L, Buithieu J, et al. First-in-human experience with the Medtronic CoreValve Evolut R. EuroInter- vention. 2014;9:1260-1263. DOI: 10.4244/ EIJV9I11A215
20. Meredith IT. 6-month outcomes following transcatheter aortic valve implantation with a novel repositionable self-expanding bioprosthesis. Presented at EuroPCR 2015.
21. Meredith IT, Hood KL, Haratani N, Allocco DJ, Dawkins KD. Boston Scientific Lotus valve. EuroIntervention. 2012;8(Suppl. Q):Q70-74. DOI: 10.4244/EIJV8SQA12
22. Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30- day primary endpoint results from the RE-
Abramowitz, Y. et al.
TAVR Devices